CytomX Therapeutics (CTMX) PT Raised at Piper Sandler Amid 'Encouraging CX-801 Data'
Tweet Send to a Friend
Piper Sandler analyst Edward Tenthoff raised the price target on CytomX Therapeutics (NASDAQ: CTMX) to $6.50 (from $5.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
